NYU Langone’S Perlmutter Cancer Center

Routine screening for financial toxicity during active cancer treatment is feasible, according to study results presented at ASCO Quality Care Symposium.

Elizabeth A. Comen, MD, has been appointed associate professor in the department of medicine at NYU Langone Health’s Perlmutter Cancer Center.

CHICAGO — Combining an mRNA-based cancer vaccine with standard-of-care pembrolizumab significantly improved RFS and distant metastasis-free survival among patients with resected high-risk melanoma, study results showed.

Jonathan T. Yang, MD, PhD, has been appointed associate vice chair for clinical research and developmental therapeutics in the department of radiation oncology at NYU Langone Health’s Perlmutter Cancer Center.

Alec Kimmelman, MD, PhD, has been appointed director of Perlmutter Cancer Center at NYU Langone Health.

Michael J. Zelefsky, MD, has been appointed director of brachytherapy for NYU Langone’s Perlmutter Cancer Center.

Results from the American Association for Cancer Research’s annual Cancer Progress Report revealed that the age-adjusted overall cancer death rate in the U.S. fell by 33% between 1991 and 2020.

CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.

CHICAGO — A novel oral aryl hydrocarbon receptor inhibitor appeared well tolerated and safe among a small cohort of patients with advanced solid tumors, according to phase 1 study results presented at ASCO Annual Meeting.

CHICAGO — A study that assessed the feasibility of lung cancer screening for certain nonsmokers yielded a higher invasive adenocarcinoma detection rate than the National Lung Screening Trial, which assessed screening for smokers who met key risk criteria.